The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Emmy Award-winning actor Eric Stonestreet, known for his portrayal of Cameron Tucker on ABC’s hit sitcom Modern Family, has revealed his private health journey with type 2 diabetes and how medication ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eric Stonestreet's life changed forever in two major ways. First, he landed his role in "Modern Family," a critically ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly reported a strong revenue jump driven by the blockbuster performance of its weight loss and diabetes drugs, ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound ...